Capio Biosciences Receives Notice of Allowance from Korean Intellectual Property Office

Capio Biosciences is pleased to announce receipt of an official Notice of Allowance for patent application # 10-2017-7035887 - "Method for monitoring efficacy of a cancer therapy using Circulating Tumor Cells as a biomarker” from the Korean Intellectual Property Office (KIPO). This patent, exclusively licensed to Capio Biosciences by the Board of Trustees of the University of Illinois; and the University of North Carolina at Chapel Hill, further strengthens the intellectual property portfolio of Capio Biosciences, and is another step toward clinical translation of CapioCyte™ technology.


Need more details? Contact us.


We are here to assist. If you require further information or are interested in collaborations or partnerships, contact us by phone, email or via our social media channels.

  • White LinkedIn Icon
  • White Twitter Icon
  • White Facebook Icon

505 S. Rosa Road
Suite 10C
Madison, WI 53719

* The CapioCyte System is currently under development and not for use in diagnostic procedures.


Capio and CapioCyte are trademarks of Capio Biosciences.